Investigators

Summary

I am Associate Professor of Medicine at the University of Pittsburgh Medical Center and Director of the Cancer Immunotherapeutics Center at Hillman Cancer Center who focuses on translational therapeutic advances for malignant melanoma and early phase drug development for advanced cancers. I have particular expertise in the immunotherapy of cancer, having been a lead investigator for immunotherapies such as anti-PD1/L1, CTLA4, LAG3, TIM3, GITR, OX40, CD137, CD40, inhibitors of indolamine-dioxygenase, adenosine A2a receptor & arginase as well as agonists of STING & oncolytic virus. I maintain an on-going interest in the molecular biology of cancer and particularly in the intersection between oncogene targeted small molecules and immunotherapy. I have pursued large scale biobanking efforts surrounding cancer immunotherapy and am interested in identifying tumor-intrinsic mechanisms of immune exclusion from patient samples by employing multi-omic bioinformatic approaches. I have been successful in obtaining independent support for clinical investigation from private, public and industry sources.